• The technology described in this briefing is UroShield. It is used to prevent catheter-associated urinary tract infections (CAUTI) in people with long-term indwelling catheters.

  • The innovative aspects are that it uses surface acoustic wave technology to prevent the attachment of bacteria to the surface of catheters.

  • The intended place in therapy would be as well as existing catheter products to help prevent infection in people with indwelling catheters.

  • The main points from the evidence summarised in this briefing are from 2 randomised controlled studies and 1 prospective non-randomised comparative study involving a total of 122 patients with indwelling urinary catheters. They show that when applied to urinary catheters, UroShield can help reduce the incidence of CAUTI and bacterial load and may help to decrease catheter-related pain.

  • Key uncertainties around the evidence or technology are that from the evidence identified on UroShield, only 1 study has been published in a peer-reviewed journal, and that study was funded by the company. The evidence is also limited in its generalisability to the NHS because none of the studies were done in the UK.

  • The cost of the UroShield system is £100 per month (£1,200 per year as a combined cost for the driver and actuator; excluding VAT). The resource impact would be an increased cost for buying the technology. There is the potential to release resources if the technology is shown to reduce the average number of CAUTIs per patient per year. The available evidence does not currently confirm that this would be the case.